louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06855251: SENSing Inner BodiLy State: Understanding the Role of Interoception in obEsity
Official title: SENSing Inner BodiLy State: Understanding the Role of Interoception in obEsity
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Obesity
Body Representation
Lead sponsor: Istituto Auxologico Italiano
Sponsor class: OTHER
First posted: 2025-03-03
Enrollment: 32
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants with obesity were consecutively recruited during their rehabilitative treatment at the Istituto Auxologico Italiano, IRCCS, San Giuseppe Hospital (Italy).

Brief summary: Successfully perceiving the flow of interoceptive cues and integrating them with exteroceptive information are fundamental aspects of countering the body's inherent instability and guaranteeing homeostatic regulation. This process deeply affects cognitive/emotional functioning and general health. Recently, it has been suggested that an important signature underpinning obesity might be an interoceptive dysfunction in perceiving internal body signals and/or integrating them with information from the external environment. There is evidence that interoceptive deficits correlate with Body Mass Index (BMI), but it is still largely unclear how different measures and facets of interoception are related to high BMI and eating behaviour. Within this framework, it is mandatory to understand the role of interoception in obesity at perceptual, cognitive, and emotional levels. One open issue regards the relationships between interoceptive signals and the reactivity to external food cues.


Eligibility criteria: Inclusion Criteria:

* Right-handed individuals diagnosed with obesity
* In rehabilitative treatment at the Istituto Auxologico

Exclusion Criteria:

* Concurrent neurological, neurodevelopmental (e.g., autism), motor, somatosensory and/or psychiatric disorders

Primary outcomes:
measure: Visual detection velocity
timeFrame: At the moment of the experiment
measure: Interoceptive judgement
timeFrame: At the moment of the experiment
Secondary outcomes:
measure: Visual detection accuracy
timeFrame: At the moment of the experiment
Other outcomes:
Locations:
city: Piancavallo
country: Italy
facility: IRCCS Istituto Auxologico Italiano - Ospedale San Giuseppe
state: VCO
Study officials:
affiliation: IRCCS Istituto Auxologico Italiano
name: Federica Scarpina, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05804851: Skin Microbiome of Chinese Population Cohort Study
Official title: Skin Microbiome of Chinese Population Cohort Study: Association Between Human Health and Skin Microbiome
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Skin Microbiome
Lead sponsor: Westlake University
Sponsor class: OTHER
First posted: 2023-04-07
Enrollment: 237
Sex: ALL
Minimum age (years): 15
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The population of this study will be selected from people that reside in Zhejiang province, and they should fulfill the eligibility criteria.

Brief summary: This observational study aims to investigate the relationship between public health and the skin microbiome in the province of Zhejiang. Due to the lack of current research on the skin microbiome, the following general questions will be investigated in this study: 1) What connection exists between dietary practices and facial skin microbiome? 2) How do people's lifestyle routines affect the facial skin microbiome? 3) What effects does the altered living environment have on people's facial skin microbiomes? 4) How do the seasons affect people's facial skin microbiomes?

Every 3 to 4 months, the participants' facial skin microbiota samples will be taken, and they will be asked to complete a survey.


Eligibility criteria: Inclusion Criteria:

* ages from 15 to 50.

Exclusion Criteria:

* a severe medical history, including a history of surgery or medication, or serious illnesses such as cancer, liver disease, kidney disease, or craniocerebral trauma.
* recent medical treatment (topical antibiotics, corticosteroids, and other anti-inflammatory drugs within 4 weeks, and systemic antibiotics, corticosteroids, and other immunosuppressive drugs within 6 months)

Primary outcomes:
measure: Changes in facial microbiota profiling
timeFrame: Day 1, Day 90, Day 180, Day 270, and Day 360
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Westlake University
state: Zhejiang
Study officials:
References:
Clinical trial NCT06896851: The Effect of Su Jok on Dysmenorrhea
Official title: The Effect of Su Jok on Dysmenorrhea:Randomized Placebo-Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dysmenorrhea
Keywords: dysmenorrhea
pain
su jok
Lead sponsor: Ankara Medipol University
Sponsor class: OTHER
First posted: 2025-03-26
Enrollment: 34
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study aims to determine the effect of Su Jok application in reducing menstrual pain.The main question it aims to answer is

-Is Su Jok practice effective in reducing the severity of dysmenorrhea? The researcher will perform a sham application to see the effect of the application.

Participants will perform the application on the first day they have pain during their 3 menstrual cycles. They will evaluate and record their pain with VAS.


Eligibility criteria: Inclusion Criteria:

* regular menstrual cycles (21-35 days)
* have abdominal pain in the last three cycles
* Those who want to participate in the study as a volunteer

Exclusion Criteria:

* have any health problems that may affect the menstrual cycle (ovarian cysts, etc.
* use hormonal medications

Primary outcomes:
measure: Pain assesment
timeFrame: " Every hour until 4 hours after the onset of pain on the first day of the cycle (each cycle is 28-35 days) and it will be for 3 cycle.
Secondary outcomes:
Other outcomes:
Locations:
city: İstanbul
country: Turkey
facility: Fenerbahçe University
state: Ataşehir
Study officials:
References:
Clinical trial NCT01794351: Cognitive Effects of 500mg Trans-resveratrol
Official title: Effects of Trans-resveratrol on Cognitive Performance in Healthy, Young Humans: a Double-blind, Placebo-controlled, Crossover Investigation.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cognitive Performance
Mood
Lead sponsor: Northumbria University
Sponsor class: OTHER
First posted: 2013-02-18
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: This study investigated the potentially cognitive enhancing effects of 500mg trans-resveratrol in healthy, young humans.


Eligibility criteria: Inclusion Criteria:

* 18-35yrs, healthy.

Exclusion Criteria:

* Drug/alcohol abuse, taking prescription medication (apart from contraception) or herbal supplements, having food intolerances or allergies, having suffered a head-injury or neurological/neuro-developmental disorder, uncorrected sight problems, pregnant or seeking to become so, excessive caffeine use (e.g. more than 6 cups of coffee per day).

Primary outcomes:
measure: Number of participants with altered cognitive function at 40mins post-dose
timeFrame: 40mins Post-dose
measure: Number of participants with altered cognitive function at 2.5hrs post-dose
timeFrame: 2.5hrs post-dose
measure: Number of participants with altered cognitive function at 4hrs post-dose
timeFrame: 4hrs post-dose
measure: Number of participants with altered cognitive function at 6hrs post-dose
timeFrame: 6hrs post-dose
Secondary outcomes:
measure: Number of participants with altered mood at 40mins post-dose.
timeFrame: 40mins post-dose
measure: Number of participants with altered mood at 2.5hrs post-dose
timeFrame: 2.5hrs post-dose
measure: Number of participants with altered mood at 4hrs post-dose
timeFrame: 4hrs pos-dose
measure: Number of participants with altered mood at 6hrs post-dose
timeFrame: 6hrs post-dose
Other outcomes:
Locations:
city: Newcastle upon Tyne
country: United Kingdom
facility: Brain performance and nutrition research centre, Northumbria university
state: Tyne and Wear
Study officials:
References:
Clinical trial NCT01622751: Plasma Adiponectin Level and Sleep Structures in Children With Prader-Willi Syndrome
Official title: Plasma Adiponectin Level and Sleep Structures in Children With Prader-Willi Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prader-Willi Syndrome
Obesity
Keywords: REM sleep
Adiponectin
Prader-Willi syndrome
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2012-06-19
Enrollment: 46
Sex: ALL
Minimum age (years): 5
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The study population comprised 28 children with PWS and 18 controls. The enrolled children with PWS were volunteers from a pool of approximately 100 children with PWS followed up at the Samsung Medical Center. The controls were healthy children from several elementary and middle schools located in the southern areas of Seoul.

Brief summary: Context: Adiponectin is an adipose tissue-derived hormone with an insulin sensitizing effect, and has been related to obstructive sleep apnea syndrome. In addition, children with Prader-Willi syndrome (PWS) suffer from excessive daytime sleepiness and the abnormality of rapid eye movement (REM) sleep.

Objective: To determine if the sleep stages are related to the plasma levels of adiponectin, resistin, and RBP4 (retinol binding protein-4), and whether these relationships are influenced by age, obesity and insulin resistance.

Detailed description: This comparative study was carried out in 28 PWS children and 18 controls. The enrolled PWS children were volunteers out of a pool of approximately 100 PWS children followed at Samsung Medical Center \[median age 8.0 years, interquartile range (7.0-10.5 years), BMI: median 24.2 kg/m2 (23.0-27.5 kg/m2)\] and 18 obese healthy children \[median age 9.0 years interquartile range (7.0-11.0 years), BMI: median 24.2 kg/m2 interquartile range (23.1-27.6 kg/m2)\].

Eligibility criteria: Inclusion Criteria:

* Prader Willi syndrome healthy children

Exclusion Criteria:

* history of seizure,
* mental or brain illness,
* adenoidectomy,
* tonsillectomy,
* craniofacial anomalies and any treatment at the time of the study.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Samsung Medical Center, Sungkyunkwan University School of Medicine
name: Dong-Kyu Jin, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03980951: Neuroaxial Labour Analgesia
Official title: A Randomized Comparison of Epidural, Dural Puncture Epidural and Combined Spinal Epidural Without Intrathecal Opioids for Labor Analgesia.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Labor Analgesia
Lead sponsor: Ain Shams University
Sponsor class: OTHER
Collaborators: name: elite medical hospital
First posted: 2019-06-10
Enrollment: 120
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized controlled trial assignment placed in sealed envelopes.
Primary purpose: TREATMENT

Brief summary: The primary outcome of this clinical trial is to compare the pain scores during labour and delivery of combined spinal epidural without intrathecal opioids and dural puncture epidural

The secondary objective of this study is to compare the and fetomaternal outcomes


Eligibility criteria: Inclusion Criteria:

1. Nulliparous parturient
2. Singleton, vertex gestation at term (37-42 weeks)
3. Less than 5 cm dilation
4. request an epidural technique for labor analgesia

Exclusion Criteria:

1. Hypersensitivity to local the study drugs
2. Clinically significant disease , including diseases of pregnancy (i.e preeclampsia, gestational diabetes)
3. Any contraindication to the administration of an epidural technique
4. Risk factor for cesarean delivery.
5. fetal anomalies

Primary outcomes:
measure: epidural Local anesthetic consumption
timeFrame: 1 year
Secondary outcomes:
measure: Maternal hypotension
timeFrame: 1 year
measure: incidence of fetal bradycardia
timeFrame: 1 year
measure: incidence of maternal pruritus
timeFrame: 1 year
measure: labour pain scores
timeFrame: 1 year
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University
state: Abbasyia
city: Kuwait
country: Kuwait
facility: Elite Hospital
state: Abbasyia
Study officials:
References:
citation: Bakhet WZ. A randomized comparison of epidural, dural puncture epidural, and combined spinal-epidural without intrathecal opioids for labor analgesia. J Anaesthesiol Clin Pharmacol. 2021 Apr-Jun;37(2):231-236. doi: 10.4103/joacp.JOACP_347_19. Epub 2021 Jul 15.
Clinical trial NCT02725151: Acute Heart Failure Monitoring Via Inferior Vena Cava Ultrasound
Official title: The Role of Inferior Vena Cava in Emergency Treatment of Acute Decompensated Heart Failure and Deciding Hospitalization
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Heart Failure
Keywords: inferior vena cava ultrasound
acute
heart failure
management
decompensation
Lead sponsor: Haseki Training and Research Hospital
Sponsor class: OTHER
First posted: 2016-03-31
Enrollment: 64
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients constitute the study population that was admitted to emergency department with complaint of dyspnea.These patients will be accepted for this study, that known Heart Failure and must be taken diuretic therapy because of volume overload.

Brief summary: Known before diagnosed heart failure and used diuretic therapy patients will be admitted in this study.The objective of this work is whether the Inferior Vena Cava Ultrasound can be used for management of Acute Heart failure therapy. And investigators will calculation correlation of extracted urine amount with Inferior Vena Cava diameter change. Researchers will not interfere to standard recommended treatment protocol, researchers will correlated the urine amount and changed vital signs with therapy with Vena cava inferior diameter.


Eligibility criteria: Inclusion Criteria:

* Adult patients (\> 18 years of age) of both sexes)
* Non-trauma patients
* Non- pregnant patients
* All patients will be accepted for this study, that known Heart Failure and must be taken diuretic therapy because of volume overload

Exclusion Criteria:

* Cardiac tamponade
* Aortic dissection
* Patients who had suffered cardiopulmonary arrest or been intubated

Primary outcomes:
measure: Vena cava inferior diameter change end of each 500cc urination
timeFrame: Maximum 3 hours
Secondary outcomes:
measure: Vena cava inferior diameter change with classic treatment at each hour
timeFrame: Maximum 3 hours
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Adnan Yamanoğlu
Study officials:
affiliation: Haseki Training and Research Hospital, Emergency Department
name: Adnan Yamanoğlu, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yamanoglu A, Celebi Yamanoglu NG, Ozturk S, Cakmak S, Akay S, Akyol PY, Sogut O. The value of the inferior vena cava ultrasound in the decision to hospitalise in patients with acute decompensated heart failure; the best sonographic measurement method? Acta Cardiol. 2021 May;76(3):245-257. doi: 10.1080/00015385.2020.1740422. Epub 2020 Mar 19.
Clinical trial NCT03685851: Post Operative Visual Acuity for DSAEK and UT-DSAEK
Official title: Post Operative Visual Acuity for Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) and UT-DSAEK
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Corneal Transplant
Lead sponsor: Centre Hospitalier Régional Metz-Thionville
Sponsor class: OTHER
First posted: 2018-09-26
Enrollment: 111
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who underwent DSAEK surgery between february 2012 and june 2017

Brief summary: To study the correlation between graft size in DSAEK (Descemet Stripping Automated Endothelial Keratoplasty) and UT (ultra thin)-DSAEK type corneal transplants to the visual acuity 6 months postoperatively.


Eligibility criteria: Inclusion Criteria:

* Patients who underwent DSAEK surgery
* Patients in department of ophthalmology between february 2012 and june 2017

Exclusion Criteria:

* None

Primary outcomes:
measure: Postoperative visual acuity
timeFrame: Month 6
Secondary outcomes:
measure: Pachymetry
timeFrame: Month 6
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00018551: Chemoprevention With Folic Acid
Official title: 3389 Colorectal Adenoma: Chemoprevention With Folic Acid
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Colon Cancer
Adenoma
Colonic Polyps
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2001-07-05
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Primary purpose: PREVENTION

Brief summary: Colorectal neoplasia is the second most common cancer in the United States and other Western countries with about 140,000 newly diagnosed cases per year in the United States with a mortality rate of about 40%. The identification of a specific natural or synthetic compound with the ability to reverse or suppress the process of colon carcinogenesis would have profound implication in the development of colorectal adenomas and their subsequent transformation to colon cancer. Furthermore, the establishment of a correlative relationship between biomarkers of cell proliferation, differentiation, apoptosis and adenoma recurrence would provide pivotal data required to elucidate cell signaling mechanisms in future colon cancer chemoprevention trials.


Eligibility criteria: Asymptomatic individuals from the age of 18 -80 years, undergoing clinically indicated colonoscopy for colon polyps noted on screening flexible sigmoidoscopy or as routine surveillance for a history of colon polyps, who are found to have at least one adenoma \> 0.5cm will be eligible for entry.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Detroit
country: United States
facility: Department of Veterans Affairs
state: Michigan
Study officials:
References:
Clinical trial NCT04848051: Implementing Fit Kit Colorectal Cancer (CRC) Screening in High Risk Populations
Official title: Implementing Fit Kit Colorectal Cancer (CRC) Screening in High Risk Populations
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colorectal Cancer
Keywords: Health Screening
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2021-04-19
Enrollment: 3127
Sex: ALL
Minimum age (years): 50
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The purpose of this study is to understand best strategies for engaging high risk populations in a primary care setting to improved adherence to colorectal cancer screening guidelines. The results will be used to identify best practices that are scalable to other high-risk populations who are due or overdue for colorectal cancer (CRC) screening.

Detailed description: This is a prospective implementation science study that will test 4 different approaches to increase colorectal cancer screening in a local primary care setting that provides services to individuals who are under-resourced. The interventions will include reminders from primary care providers with and without additional information and/or services to help complete colorectal cancer screening. A review of electronic medical records will be used to identify baseline information assessing risk factors and personal and family CRC history. For arm 3 of the study, participants may elect to enroll in our existing health navigation program. If so, additional baseline information will be collected, including information on Social Determinants of Health (SDOH). For arm 4 of the study, a questionnaire will be used to assess knowledge about colorectal cancer screening. The questionnaire will be repeated after the intervention (informational video). For all arms of the study, the primary outcome (engagement on CRC screening, receipt of CRC screening, results of CRC screening) will be collected through EPIC.

Eligibility criteria: Inclusion Criteria:

* be 50-74 years of old at the time of enrollment
* have one valid medical encounter with CSHHC Columbus Ave. location or Dixwell location between the dates of 11/01/2019 and 11/30/2020

Exclusion Criteria:

• Documented history of colorectal cancer

Primary outcomes:
measure: Total number of participants who completed their colorectal cancer screening
timeFrame: 18 months
Secondary outcomes:
measure: Time to engagement
timeFrame: 18 months
measure: Screening outcomes: results of screening
timeFrame: 18 months
measure: Screening outcomes: follow up
timeFrame: 18 months
measure: Screening outcomes: biopsy results
timeFrame: 18 months
measure: Screening outcomes: diagnostic results
timeFrame: 18 months
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Cornell Scott Hill Health Center
state: Connecticut
Study officials:
affiliation: Yale University
name: Beth Jones
role: PRINCIPAL_INVESTIGATOR
References: